-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143

Benzinga·08/05/2026 19:20:04
Listen to the news
Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $142 to $143.